MICHAEL A DAVIES to Cyclin-Dependent Kinase Inhibitor p16
This is a "connection" page, showing publications MICHAEL A DAVIES has written about Cyclin-Dependent Kinase Inhibitor p16.
Connection Strength
0.024
-
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res. 2013 Sep 01; 19(17):4868-78.
Score: 0.024
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.